Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis
Status:
Suspended
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Phase I / II randomized, single-blind, placebo-controlled clinical trial to evaluate the
safety and efficacy of melatonin administration combined with ocrelizumab in patients with
Progressive Multiple Primary Sclerosis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla